Advances in pharmacotherapy for tobacco dependence
Foulds, Jonathan ; Burke, Michael ; Steinberg, Michael ; Williams, Jill M. ; Ziedonis, Douglas M.
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
Blood-Brain Barrier
Clinical Trials as Topic
Combined Modality Therapy
Comorbidity
Drug Administration Routes
Drug Design
Drug Evaluation, Preclinical
Drug Therapy, Combination
Health Education
Humans
Marketing
Mental Disorders
Nicotine
effects
Nicotinic Antagonists
Rats
Smoking
Smoking Cessation
Social Support
Substance Withdrawal Syndrome
Tobacco Use Disorder
Vaccines
Psychiatry
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.
Source
Expert Opin Emerg Drugs. 2004 May;9(1):39-53. Link to article on publisher's site